Loading…

A Differential Item Functioning Analysis of the EQ-5D in Cancer

Abstract Objectives To determine whether differential item functioning (DIF) was present in the EuroQol five-dimensional questionnaire (EQ-5D) used in cancer (non–small cell lung cancer and prostate cancer). Methods The Partial Credit Model was applied to the three-level version of the EQ-5D with da...

Full description

Saved in:
Bibliographic Details
Published in:Value in health 2016-12, Vol.19 (8), p.1063-1067
Main Authors: Smith, Adam B., PhD, Cocks, Kim, PhD, Parry, David, MSc, Taylor, Matthew, PhD
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objectives To determine whether differential item functioning (DIF) was present in the EuroQol five-dimensional questionnaire (EQ-5D) used in cancer (non–small cell lung cancer and prostate cancer). Methods The Partial Credit Model was applied to the three-level version of the EQ-5D with data obtained from four randomized controlled trials in prostate cancer and non–small cell lung cancer completed at baseline before treatment (N = 2213). DIF was assessed across cancer type (two levels), sex (two levels), and age group (three levels) using Mantel-Haenszel chi-square statistics and evaluated against the Educational Testing Service classification rules. Results The presence of DIF was determined in 14 of 25 (56%) potential DIF contrasts in all the EQ-5D domains. Although mostly the DIF was categorized as either negligible (3 of 25 [12%]) or medium (7 of 25 [28%]), large DIF was observed in 4 of the 25 contrasts (16%). The mobility domain, in particular, showed consistently large DIF across cancer type, sex, and age. Conclusions Given the use of the instrument in health status assessments across conditions and interventions, these results may have significant implications for the EQ-5D in health economic evaluations. Further research is warranted to determine whether these results hold for other cancers.
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2016.06.005